| Literature DB >> 22805313 |
Ji Young Kim1, Ju Yeon Park, Hee Jung Kang, Oh Yoen Kim, Jong Ho Lee.
Abstract
BACKGROUND: The reported health benefits of Korean red ginseng (KRG) include antioxidant, antitumor, antimutagenic, and immunomodulatory activities; however, the effects on oxidative stress have not yet been evaluated. Therefore, we assessed the effect of KRG on antioxidant enzymes and oxidative stress markers in humans.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22805313 PMCID: PMC3426460 DOI: 10.1186/1475-2891-11-47
Source DB: PubMed Journal: Nutr J ISSN: 1475-2891 Impact factor: 3.271
Anthropometric parameters and blood pressure before and after intervention
| Age (yr) | 37.0 ± 2.24 | 36.4 ± 1.73 | 35.3 ± 1.68 | 0.910 | |||
| Male / Female (n) | 7/12 | 7/12 | 9/10 | 0.747 | |||
| Body mass index (BMI; kg/m2) | | | | | | ||
| Pre-treatment | 23.4 ± 0.60 | 24.0±0.93 | 23.5±0.70 | | |||
| Post-treatment | 23.6 ± 0.67 | 24.3±0.93 | 23.6±0.65 | | |||
| Change | 0.27±0.16 | 0.26±0.15 | 0.11±0.14 | 0.850 | |||
| Cigarette smoker, n (%) | 8 (42.1) | 6 (31.6) | 8 (42.1) | 0.948 | |||
| Alcohol drinker, n (%) | 15 (78.9) | 13 (68.4) | 13 (68.4) | 0.706 | |||
| Blood pressure (mmHg) | | | | | |||
| Systolic blood pressure (mmHg) | |||||||
| Pre-treatment | 115.3±2.92 | 118.8±3.22 | 117.5±2.32 | | |||
| Post-treatment | 114.7±2.08 | 118.8±3.10 | 118.2±1.94 | | |||
| Change | −0.55±1.97 | −0.03±0.19 | 0.74±1.65 | 0.740 | |||
| Diastolic blood pressure (mmHg) | |||||||
| Pre-treatment | 76.6±1.83 | 80.6±1.98 | 78.4±1.81 | | |||
| Post-treatment | 75.6±1.93 | 77.3±2.14* | 76.2±1.71 | ||||
| Change | −0.92±1.88 | −3.29±1.28 | −2.16±1.75 | 0.599 | |||
Results are expressed as mean ± standard error of the mean (SEM) or n (%).
Baseline values for the placebo and test groups were not significantly different (nonparametric Kruskal-Wallis test).
*P < 0.05 compared with the baseline in each group (Wilcoxon signed-rank test).
a) Evaluated by nonparametric Kruskal-Wallis test.
Daily energy expenditure and nutrient intake before and after intervention
| Total energy expenditure (kcal) | | | | |
| Pre-treatment | 2329.3±78.9 | 2331.8±90.5 | 2299.5±57.6 | |
| Post-treatment | 2268.3±76.7 | 2273.2±98.1 | 2300.0±68.1 | |
| Change | −61.0±36.9 | −58.6±33.6 | 0.50±32.9 | 0.317 |
| Estimates of dietary nutrient intake | | | | |
| Total calorie intake (kcal) | | | | |
| Pre-treatment | 1789.2±79.6 | 1726.4±104.4 | 1847.9±114.2 | |
| Post-treatment | 1892.9±72.9 | 1820.1±81.9 | 1966.3±97.8 | |
| Change | 103.7±79.0 | 93.7±69.1 | 118.4±75.1 | 0.991 |
| Carbohydrate (%) | | | | |
| Pre-treatment | 60.0±1.57 | 60.8±1.09 | 62.4±0.92 | |
| Post-treatment | 61.2±1.66 | 59.9±1.72 | 61.1±1.34 | |
| Change | 1.16±1.78 | −0.94±1.78 | −1.28±1.44 | 0.767 |
| Protein (%) | | | | |
| Pre-treatment | 16.0±0.61 | 16.3±0.62 | 15.8±0.42 | |
| Post-treatment | 16.5±0.75 | 16.0±0.61 | 15.4±0.53 | |
| Change | 0.56±0.86 | −0.36±0.75 | −0.38±0.67 | 0.280 |
| Fat (%) | | | | |
| Pre-treatment | 24.4±1.47 | 23.9±1.05 | 22.4±1.07 | |
| Post-treatment | 22.7±1.79 | 24.3±1.55 | 22.9±1.14 | |
| Change | −1.67±1.65 | 0.43±1.22 | 0.50±1.22 | 0.733 |
| TEE/TCI | | | | |
| Pre-treatment | 1.37±0.11 | 1.43±0.09 | 1.34±0.09 | |
| Post-treatment | 1.23±0.06 | 1.29±0.08 | 1.23±0.07 | |
| Change | −0.14±0.10 | −0.14±0.07 | −0.12±0.07 | 0.990 |
Results are expressed as standard error of the mean (SEM).
No significant differences in the week 0 value between the placebo and test groups were found by nonparametric Kruskal-Wallis test.
a) Evaluated by nonparametric Kruskal-Wallis test.
Antioxidant enzyme activity and lipid peroxidation before and after intervention
| SOD activity (U/ml) | | | | |||
| Pre-treatment | 12.6±0.97 | 10.1±0.68 | 11.9±0.98 | |||
| Post-treatment | 12.2±0.96 | 12.1±1.03* | 14.2±1.15* | |||
| Change | −0.46±0.57 | 1.95±0.80 | 2.24±0.86† | |||
| GPx activity (nmol/min/ml) | | | | |||
| Pre-treatment | 41.1±3.71 | 34.3±1.88 | 34.9±2.53 | |||
| Post-treatment | 39.1±3.72 | 37.4±2.27 | 43.5±2.53** | |||
| Change | −2.00±2.08 | 3.05±2.15 | 8.66±2.63† | |||
| Catalase (nmol/min/ml) | | | | |||
| Pre-treatment | 103.2±11.5 | 94.5±8.56 | 86.9±11.7 | |||
| Post-treatment | 99.0±13.2 | 118.3±11.8 | 135.5±12.3** | |||
| Change | −4.17±12.4 | 23.8±12.4 | 48.5±12.3† | |||
| 8-epi-PGF2α (pg/mg creatinine)a) | | | ||||
| Pre-treatment | 1450.3±103.7 | 1519.0±222.3 | 1516.3±105.9 | |||
| Post-treatment | 1641.6±136.5 | 1323.4±106.6 | 1383.5±120.2 | |||
| Change | 191.3±107.7 | −195.6±147.6† | −132.8±127.9† | |||
SOD, superoxide dismutase; GPx, glutathione peroxidase; 8-epi-PGF2α, 8-epi-prostaglandin F2α.
a)Tested after logarithmic transformation.
Results are expressed as standard error of the mean (SEM).
Tested by Wilcoxon signed-rank test or analysis of covariance (ANCOVA) using a general linear model (GLM) with adjustments for age, sex, BMI, smoking, drinking, systolic BP, diastolic BP, and baseline values.
*P <0.05,**P <0.01 compared with the baseline in each group; †P <0.05, ††P <0.01 compared with the placebo group.
Figure 1 Effects of 8-week supplementation of Korean red ginseng (KRG) on lymphocyte DNA damage LDL oxidation. A. Comparison of mean values for damaged tail length (μm) and tail moment in lymphocyte DNA and the concentrations of oxidized LDL (U/L). B. Images of lymphocyte DNA damage performed by comet assay before and after treatment between the placebo and high-dose groups. ∮Tested after log transformation. P values represent significant differences by analysis of covariance (ANCOVA) using a general linear model (GLM) with adjustments for age, sex, BMI, smoking, drinking, systolic BP, diastolic BP, and baseline values. *P <0.05,**P <0.01, and ***P <0.001 compared with the baseline in each group; †P <0.05, ††P <0.01 , †††P <0.001 compared with the placebo group.